Withdrawal of Registration Statement (ammendment) (aw)
May 27 2022 - 4:31PM
Edgar (US Regulatory)
Indaptus
Therapeutics, Inc.
3
Columbus Circle, 15th Floor
New
York, NY 10019
May
27, 2022
VIA
EDGAR
Securities
and Exchange Commission
Division
of Corporation Finance
100
F Street, N.E.
Washington,
D.C. 20549
Re: |
Indaptus
Therapeutics, Inc. |
|
Registration
Statement on Form S-3 |
|
Post-Effective
Amendment No. 1 dated August 16, 2021 and filed on August 16, 2021 and
Post-Effective Amendment No. 1 dated August 16, 2021 and filed on August 18, 2021 |
|
File
No. 333-258854 |
Ladies
and Gentlemen:
Pursuant
to Rule 477 under the Securities Act of 1933, as amended (the “1933 Act”), Indaptus Therapeutics, Inc. (the “Company”)
hereby requests that the Securities and Commission (the “Commission”) consent to the withdrawal of (i) the Post-Effective
Amendment No. 1 (SEC Accession No. 0001493152-21-020209) (the “First Post-Effective Amendment”) to the Company’s Registration
Statement on Form S-3 (the “Registration Statement”), together with all exhibits filed therewith, filed on August 16, 2022,
and (ii) the Post-Effective Amendment No. 1 (SEC Accession No. 0001493152-21-020550) (the “Second Post-Effective Amendment”
and together with the First Post-Effective Amendment, the “Post-Effective Amendments”) to the Registration Statement, together
with all exhibits filed therewith, filed on August 18, 2022. The First Post-Effective Amendment inadvertently referenced 1933 Act file
number 333-258854, but when filed could not be associated with the correct 1933 Act file number 333-230016 for certain technical reasons
at such time. The Second Post-Effective Amendment referenced the correct 1933 Act file number 333-230016, but when filed could still
not be associated with such 1933 Act file number for technical reasons at such time. The withdrawal hereby requested is only for the
Post-Effective Amendments that were filed on August 16, 2022 and on August 18, 2022, and not with respect to any other filings made under
the 1933 Act file numbers 333-258854 or 333-230016. The Post-Effective Amendments have not been declared effective by the Commission
and no securities have been sold under the Post-Effective Amendments.
Please
direct any questions or comments regarding this correspondence to Gary Emmanuel of McDermott Will & Emery LLP at (212) 547-5541.
Thank
you for your assistance in this matter.
|
Very
truly yours, |
|
|
|
INDAPTUS
THERAPEUTICS, INC. |
|
|
|
|
By:
|
/s/
Jeffrey A. Meckler |
|
Name:
|
Jeffrey
A. Meckler |
|
Title:
|
Chief
Executive Officer |
Indaptus Therapeutics (NASDAQ:INDP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Indaptus Therapeutics (NASDAQ:INDP)
Historical Stock Chart
From Jul 2023 to Jul 2024